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Is drug-resistant Mycobacterium leprae a real cause for concern? 
First approach to molecular monitoring of multibacillary Colombian 
patients with and without previous leprosy treatment
Martha Inírida Guerrero, Claudia Lucía Colorado, José Fernando Torres, Clara Inés León
Centro Dermatológico Federico Lleras Acosta, E.S.E., Bogotá, D.C., Colombia
Introduction: There is no information in Colombia on Mycobacterium leprae primary and secondary 
drug resistance in regards to the WHO-multidrug therapy regime. On the other hand, public health 
authorities around the world have issued various recommendations, one of which prompts for the 
immediate organization of resistance surveillance through simple molecular methods.
Objective: To determine the prevalence of Mycobacterium leprae drug resistance to rifampicin, ofloxacin 
and dapsone in untreated and previously treated patients at the Centro Dermatológico Federico Lleras 
Acosta during the 1985-2004 period.
Materials and methods: We conducted a retrospective study which included multibacillary patient 
biopsies through elective sampling: 381 of them from new patients and 560 from previously treated 
patients. Using a microtome, we obtained six slides from each skin biopsy preserved in paraffin, and we 
extracted M. leprae DNA. We amplified three molecular targets through PCR and obtained the patterns 
of drug resistance to dapsone, rifampicin and ofloxacin by reverse hybridization. Finally, we collected 
epidemiological, clinical and demographical data for analyses. 
Results: From 941 samples under study, 4.14% of them were resistant to one or more drugs, and 
5.77 and 3.04% had resistant genotypes in new and previously treated patients, respectively. Total 
resistance for each drug was 0.43% for dapsone, 3.19% for rifampicin and 1.17% for ofloxacin. We 
found statistically significant differences for rifampicin and for the total population when comparing 
the results from untreated versus previously treated patients. Two thirds of the resistant samples were 
resistant to rifampicin alone or combined. 
Conclusions: The standard multidrug therapy schemes continue being effective for leprosy cases; 
however, it is necessary to guarantee adherence and regularity. Surveillance to drug resistance in new 
and previously treated leprosy cases should be established.
Key words: Mycobacterium leprae, drug resistance, rifampicin, dapsone, ofloxacin, molecular detection, 
Colombia, PCR
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¿Es la resistencia de Mycobacterium leprae a los medicamentos un verdadero motivo de 
preocupación? Primera aproximación a la vigilancia molecular de pacientes colombianos 
multibacilares con tratamiento previo para lepra y sin él
Introducción. Colombia no dispone de información sobre farmacorresistencia primaria y secundaria de 
Mycobacterium leprae al esquema de terapia múltiple de la Organización Mundial de la Salud (OMS) y 
las autoridades de salud pública del mundo han emitido varias recomendaciones, entre las cuales está 
organizar de inmediato la vigilancia a la resistencia empleando métodos moleculares simples.
Objetivo. Determinar la prevalencia de la resistencia de M. leprae a rifampicina, ofloxacina y dapsona 
en pacientes del Centro Dermatológico Federico Lleras Acosta con tratamiento previo y sin él durante 
el período de 1985 a 2004.
Materiales y métodos. Se realizó un estudio retrospectivo. Mediante muestreo electivo se incluyeron 
biopsias de pacientes multibacilares: 381 de pacientes nuevos y 560 de pacientes previamente 
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tratados. Se obtuvieron con micrótomo seis cortes de cada biopsia de piel incluida en parafina, y se 
realizó la extracción de ADN de M. leprae. Se llevó a cabo la amplificación de tres blancos moleculares 
mediante PCR y se obtuvieron los patrones de resistencia a los medicamentos dapsona, rifampicina 
y ofloxacina por hibridación inversa. Se recolectaron datos epidemiológicos, clínicos y demográficos 
para llevar a cabo los análisis.
Resultados. De las 941 muestras estudiadas, 4,14 % era resistente a uno o más fármacos, y se 
detectaron 5,77 y 3,04 % con genotipos resistentes en pacientes nuevos y previamente tratados, 
respectivamente. La resistencia total para cada fármaco fue de 0,43 % a dapsona, 3,19 % a 
rifampicina y 1,17 % a ofloxacina. Se encontró una diferencia estadísticamente significativa para 
rifampicina y para la población total al comparar los resultados de los pacientes no tratados con los 
de los pacientes tratados previamente. Dos tercios de las muestras resistentes lo fueron a rifampicina 
sola o combinada.
Conclusiones. Los esquemas de terapia múltiple estándar siguen siendo efectivos para los casos de 
lepra; sin embargo, es necesario garantizar el cumplimiento y la regularidad y establecer la vigilancia 
de la farmacorresistencia en pacientes nuevos y previamente tratados.
Palabras clave: Mycobacterium leprae, resistencia a los medicamentos, rifampicina, dapsona, 
ofloxacina, detección molecular, Colombia, PCR.
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Leprosy control is based on the principle that 
identifying and treating chronic infectious diseases 
with an effective combination of antibiotics limits the 
emergence and expansion of both new and existing 
drug-resistant pathogens (1). In this frame, WHO 
multidrug therapy has shown to be effective since its 
introduction in 1982, but, nevertheless, it is important 
to monitor drug resistance trends periodically and 
genotype Mycobacterium leprae strains in order to 
understand resistant strains transmission patterns 
and genetic diversity. In contrast to what we know 
about tuberculosis, the prevalence of primary and 
secondary resistance is unknown for drugs used 
in multidrug therapy for leprosy such as dapsone, 
rifampicin and ofloxacin. Consequently, the risk of 
resistance cannot be assessed and a regimen for 
retreatment cannot be appropriately designed.
Mycobacterium leprae resistance to dapsone, 
rifampicin and ofloxacin has been studied in countries 
with high leprosy prevalence, like some in Southeast 
Asia (2). However, complete quantification of the 
magnitude of the drug resistance problem is crucial 
to evaluating the efficacy of multidrug therapy and 
maintaining the efficiency of current leprosy-control 
strategies around the world. Moreover, knowing the 
initial M. leprae susceptibility to drugs in patients who 
are initiating treatment and in those previously treated 
would be beneficial as a surveillance strategy. 
Given its complexity, the classic detection 
methodology for drug susceptibility of M. leprae 
using mice footpads cannot be the tool of choice 
for these purposes (3). In this sense, progress in 
molecular biology and knowledge of molecular 
mechanisms of resistance (4) offer a unique 
opportunity to determine M. leprae in vitro drug 
susceptibility, which has agreed in multiple studies 
with the results obtained from mouse footpads, for 
which these methodologies have been accepted 
worldwide (5). 
Resistance to dapsone, rifampicin and ofloxacin 
evolves by amino acid substitution at their binding 
sites. These changes are determined by mutations 
in the drug resistance-determining region (DRDR) 
in the folP1, rpoβ, and gyrA genes which have 
demonstrated to confer resistance to dapsone, 
rifampicin, and ofloxacin, respectively. By defining 
resistance mechanisms it is possible to use DNA-
based assays, namely PCR-direct DNA sequencing 
or reverse hybridization to examine susceptibility to 
these drugs (6-19).
In spite of all this information being available, few 
molecular studies have been conducted on strains 
in which drug resistance is suspected (20), and, 
therefore, the current situation is not known. For this 
reason, resistance surveillance in M. leprae, as well 
as the evaluation of treatment regime efficacy and 
control program impact, is justified (20). Among the 
few studies of drug resistance in leprosy carried out 
in the world, we can cite those reported in table 1.
It is alarming to find scientific reports on M. 
leprae cases with multiresistance to rifampicin, 
ofloxacin and dapsone, which, albeit few, ring an 
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alarm about the possibility that one of the causes 
of therapeutic failure may be the presence of 
multiresistance (17-19).
In this context, both WHO and the Informal 
Consultation on Leprosy Resistance to Rifampicin, 
held in 2006, issued several recommendations 
among which there is one prompting for the 
immediate organization of surveillance to resist-
ance through already available simple molecular 
methods applicable to many types of samples that 
can differentiate the mutations affecting different 
drugs (30).
Considering the lack of data on M. leprae primary 
and secondary resistance to the WHO multidrug 
therapy in Colombia, we conducted the present 
study to determine the prevalence of M. leprae 
drug resistance to rifampicin, ofloxacin and dapsone 
in untreated and previously treated patients at the 
Centro Dermatológico Federico Lleras Acosta in 
Bogotá, during the 1985-2004 period.
Materials and methods
Study population 
We conducted a retrospective study of skin biopsies 
from Colombian patients attending the Centro 
Dermatológico Federico Lleras Acosta, E.S.E., for 
leprosy diagnosis or multidrug therapy follow-up 
during the 1985-2004 period.
Sample 
By elective sampling, we obtained skin biopsies 
from the Centro Dermatológico Federico Lleras 
Acosta, E.S.E., biobank. We used 381 biopsies 
from new patients (samples taken for Hansen’s 
disease diagnosis and classification). To be 
included, biopsies had to be classified as belonging 
to multibacillary cases according to any of the 
criteria used in Colombia for this purpose: positive 
ZN in histopathology, positive ZN at skin smear 
examination and/or clinical examination consistent 
with leprosy. We also included 560 biopsies of 
patients previously treated for multibacillary leprosy 
(samples taken to monitor or control the disease), 
specifically when multidrug therapy failure had 
been observed or when drug resistance or relapse 
was suspected.
Obtention of histological slides and DNA 
extraction
Skin biopsies preserved in paraffin blocks were 
cut with a Leica® microtome and six slides (4 μm 
thick) were obtained using a disposable blade for 
each sample. The slides were placed in 1.5 ml 
microtubes, and stored at room temperature until 
processing. We then proceeded to the extraction 
of M. leprae DNA from the cuts adding 400 μl of 
TET buffer 1X (Triton X-100 1% TE1X buffer) to 
each sample and boiling for 15 minutes until it 
Table 1. Summary of primary and secondary published studies
Place Year
 Patients 
(n)
Resistance (%) Characteristics Ref
Untreated patients
India (Bombay)
India (Karigiri)
Indonesia
Myanmar
Philippines
South America
Bolivia
Brazil
Venezuela
Uruguay
Previously treated patients
French Polynesia
Cuba
China
India
India (Karigiri)
Indonesia
Myanmar
Philippines
Mexico
South America
1996
2002
2007
2011
1989
1993
2001
2002
2002
2007
2010
2011
3
170
121
54
77
10
24
197
2
39
9
5
214
211
10
24
19
38
3
DDS=33, MDR=33
DDS=5.88, RIF=2.35, CLOF=9,41
DDS=0,8, RIF=3,3, OFX=ND
DDS=7,2, RIF=1,8, OFX=0
DDS=2,6, RIF=0, OFX=0
DDS=0, RIF=0, OFX=0
DDS=4,2, RIF=4,2, OFX=0
DDS=0,5, RIF=0, OFX=0
DDS=0, RIF=0, OFX=0
RIF=59
DDS=33, DDS+RIF=11
RIF=0
DDS=15,6, RIF=0, DDS+CLOF=1, CLOF=1,6
DDS=6,6, RIF=0,47, CLOF=1,89 MDR=0.3
DDS=10, RIF=20, OFX=ND
DDS=8,3, RIF=8,3, OFX=0
DDS=26, RIF=0, OFX= 0
DDS=0, RIF=7,9, OFX= 2,6
DDS=66, RIF=33
New
New
New
New
Monotherapy
Relapses
Relapses
Relapses
Relapses
Relapses
MDT
Relapses
21
22
23
24
25
26
27
28
22
23
29
24
DDS: Dapsone, MDR: Multidrug resistance, RIF: Rifampicin, CLOF: Clofacimine, OFX: Ofloxacine, ND: Not determined, MDT: Multidrug therapy
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was soluble to remove the paraffin from the tissue. 
After that, a treatment with proteinase K (10 mg/
ml), NaCl 5M, chloroform and isopropanol was 
performed, and finally the pellet was washed with 
ethanol, dried and hydrated with TE buffer 0.1X, 
keeping it at -20°C until use (31).
PCR amplification of molecular targets for 
the detection of Mycobacterium leprae drug 
resistance to rifampicin, ofloxacin and dapsone
Using the methodology described previously by 
Torres (31), we amplified a 388 pb fragment from 
folP1 gene, a 304 pb fragment from rpoβ gene and 
390 pb fragment from gyrA gene using the primers 
shown in Annex 1.
Reverse hybridization. To obtain the patterns 
of drug resistance to dapsone, rifampicin and 
ofloxacin, reverse hybridization was performed 
using all the amplified fragments with the three 
molecular targets (31). The reverse hybridization 
was performed over a nylon membrane, which 
had irreversibly joined the wild and mutated 
oligonucleotides to each gene, as described in 
Annex 1 (31).
For all procedures, three samples of M. leprae 
reference DNA, kindly donated by Colorado 
University (USA), were used as controls: T-53, TM-
4923 and TM-4316.
Statistical analysis. Results for drug resistance, 
as well as the epidemiological, clinical and 
demographic information of each patient, collected 
from medical records, were entered into a database 
created in Excel 5.0 for further analysis of variables 
using Epi-Info 7.0, which was done by comparing 
proportions; confidence intervals were set to a 
significance level of 0.05.
Results
Mutations found in resistant genotypes
Specific mutations for dapsone were detected in 
folp1 codons 53 and 55. 
For rifampicin, mutations were found in rpoβ 
codons 531, 526 and 516, and, besides, a possible 
insertion was detected between codons 515 and 
520. The mutation in codon 531 was the most 
frequent. Mutations in codons other than 531 were 
present only in samples taken as of 2001.
As regards ofloxacin, mutations were detected 
at codons 89 and 91 in gene gyrA ; all samples 
with double mutation corresponded to previously 
treated patients.
Table 2 shows the characteristics of cases with 
genotypes associated with dapsone, rifampicin and 
ofloxacin resistance.
Prevalence of drug resistance 
We found primary and secondary drug resistance in 
both groups of patients (table 3). Using the Mantel-
Haenszel chi-square statistic we found statistically 
significant differences (p<0.05) for rifampicin when 
comparing results from untreated patients versus 
previously treated patients.
Description of the genotypes associated with 
drug resistance
Among the 941 samples under study, 4.14% 
(n=39) were resistant to one or more drugs; of 
the 381 samples taken from new patients, 5.77% 
(n=22) carried mutant genotypes associated with 
resistance to the drugs under study. Of the remaining 
560 biopsies from previously treated patients, 
3.04% (n=17) showed mutant genotypes associated 
with drug resistance (table 4). Statistically significant 
differences were found for rifampicin (p<0.001) and 
for the total population (p<0.05) when comparing 
the results from untreated patients versus those 
from previously treated patients (table 4).
Figure 1 shows the distribution percentage of 
all samples (n=39) where mutant genotypes 
associated with resistance to the drugs under 
study were found.
The study time was divided into four-year periods 
with an increasing number of samples but a stable 
percentage of mutant genotypes associated with 
drug resistance: 1.56% (CI95% 0.26-5.06) for the 
first period, 5.0% (CI95% 2.46-8.97) for the second 
period, 2.8% (CI95% 1.03-6.11) for the third 
period, 3.11% (CI95% 1.37-6.05) for the fourth 
period, and 5.28% (CI95% 3.15-8.25) for the fifth 
one. This means the difference in the percentages 
throughout time was not statistically significant in 
this study (figure 2).
Analysis of the demographic, clinical and 
epidemiological variables 
We analyzed the demographic variables of the 
study population discriminating by genotypes 
associated or not with resistance. A statistically 
significant difference was found between the 
proportion of patients born in the Santander 
province who had genotypes associated with 
drug resistance and those with non-associated 
genotypes (p<0.01). This same situation arose 
when we analyzed these patients’ municipality 
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Table 2. Description of cases with genotypes associated with drug resistance
  Year
Treatment Drug resistance results
Previously Regularity DDS Rifampicin Ofloxacin
1986
1987
1989
1989
1990
1991
1991
1991
1992
1992
1992
1993
1993
1994
1994
1996
2000
2000
2000
2001
2001
2001
2002
2002
2002
2003
2003
2003
2003
2003
2004
2004
2004
2004
2004
ND
ND
ND
ND
No
No
No
No
Monotherapy+MDT(3)
MDT(3)
Monotherapy+MDT(3)
No
MDT(3)
No
No
MDT(4)
Monotherapy+MDT(4)
MDT(4)
MDT(3)
No
No
No
No
No
MDT(4)
MDT(3)
MDT(3)
No
No
MDT(3)
MDT(3)
MDT(3)
MDT(3)
No
No
No
No
MDT(4)
MDT(3)+MDT(4)
No
No
No
No
NA
NA
NA
NA
Regular
Fitful
Fitful
NA
Regular
NA
NA
Regular
Regular
Regular
Regular
NA
NA
NA
NA
NA
Regular
Regular
Regular
NA
NA
Regular
Regular
Fitful
Regular
NA
NA
NA
NA
Regular
Regular
NA
NA
NA
NA
Wild
Wild
Wild
Wild
Pro55Leu
Pro55Leu
Thr53Ile
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Thr53Ala
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Ser425Leu
Wild
Ser425Leu
Ser425Leu
Wild
Wild
Ser425Leu
Ser425Leu
Ser425Met
Ser425Leu
Ser425Leu
Wild
Ser425Leu
Wild
Ser425Met
Ser425Leu
Ser425Leu
Ser425Leu
Wild
Asp410Asn
Ser425Leu
Asp410Tyr 
Asp410Tyr 
Ser425Leu
Ser425Leu
Wild
Ser425Leu
Ser425Leu
Ser425Leu
Wild
?410-420 Ω
?410-420 Ω
?410-420 Ω
Ser425Leu
His420Tyr
His420Tyr
His420Tyr
Asp410Tyr 
Wild
Wild
Ala91Val
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Gly89Cys and Ala91Val
Ala91Val
Gly89Cys and Ala91Val
Wild
Wild
Wild
Wild
Ala91Val
Wild
Ala91Val
Wild
S
Ala91Val
Ala91Val
Ala91Val
Wild
Wild
Wild
Ala91Val
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Wild
Ala91Val
NA: Not applicable, MDT: Multidrug therapy (number of drugs included)  
Table 3. Prevalence of Mycobacterium leprae drug resistance to each drug studied
Drugs Patients pa
Untreated 
(n=381)
Previously treated
(n=560)
Total
(n=941)
n % (95%CI) n % (95%CI) n % (95%CI)
Dapsone
Rifampicin
Ofloxacin
0
18
6
0.0
4.72 (1.88-11.2)
1.16 (0.31-6.68)
4
12
5
0.71 (0.10-4.0)
  2.14 (0.69-6.19)
  0.9   (0.15-4.32)
4
30
11
0.43 (0.06-2.4)
3.19 (1.5-6.32)
  1.17 (0.35-3.57)
   0.082
<0.05b
   0.169
a p: Fisher exact test significance, b p<0.05: Significant result of Fisher exact test
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Figure 1. Distribution of drug-resistant 
genotypes among the total number of 
resistant cases (n=39)
Figure 2. Number of samples and 
percentage of drug resistance for 
each four-year period
Table 4. Description of drug resistance genotypes found
Genotype Patients   pa
Untreated 
(n=381)
Previously treated
(n=560)
 Total
 (n=941)
n % (95%CI) n % (95%CI) n   % (95%CI)
Dapsone R a
Rifampicin R
Ofloxacin R
Rifampicin R + Ofloxacin R
Rifampicin R + Dapsone R
Ofloxacin R + Dapsone R
Total
0
16
4
2
0
0
22
0.00
4.02 (1,5-10,4)
1.05 (0,14-5,8)
0.52 (0,03-5,0)
0.00
0.00
  5.77 (3.84-8.74)
2
9
2
2
1
1
17
  0.4   (0,02-3,4)
1.61 (0,4-5,4)
  0.4   (0,02-3,4)
  0.4   (0,02-3,4)
0.18 (0,0-3,1)
0.18 (0,0-3,1)
    3.04 (1.83-4.91)
2
25
6
4
1
1
39
  0.21 (0,01-2,1)
2.59 (1,2-5,6)
  0.62 (0,12-2,7)
  0.42 (0,06-2,4)
0.10 (0,0-1,8)
0.10 (0,0-1,8)
  4.14 (3.0-5.67)
   0.200
  <0.001b
   0.096
   0.349
   0.655
   0.655
<0.05b
R: Resistance, a p: Fisher exact test significance, b p<0.05: Significant result of Fisher exact test
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of birth, especially in the case of Suaita (p<0.01) 
and Barrancabermeja (p<0.05) municipalities, 
both located in the Santander province (table 5). 
Although in the Cundinamarca province the said 
difference was not found, one of its municipalities, 
Agua de Dios, did present a similar situation due 
to the fact that this is one of the municipalities with 
the highest prevalence of leprosy cases in the 
country (table 5). 
None of the other demographic variables were 
related to genotypes associated with drug resis-
tance, except for province/municipality of origin, 
which behaved  the same as province/municipality 
of birth (table 5).
We analyzed the clinical variables related to the 
total population of the study discriminating by 
genotypes associated or not with drug resistance. 
Statistically significant differences were found for 
patients classified as having polar lepromatous 
leprosy (LL)  (p<0.01) versus no LL, and patients 
with positive Zielhn-Neelsen (ZN) histopathology 
(p<0.001) versus negative ZN. The rest of the 
clinical variables were not associated with the 
presence of mutant genotypes. 
The epidemiological variables were also analyzed 
according to the presence or absence of genotypes 
associated with drug resistance. The proportion 
of patients with previous monotherapy among 
carriers of mutant genotypes associated with drug 
resistance was significantly larger (p<0.001) (table 
6). The rest of the epidemiological variables under 
study did not show any differences. 
Discussion 
The present study offers valuable information 
since it included a high number of samples from 
patients with multibacillary leprosy from almost all 
the Colombian territory examined at the Centro 
Dermatológico Federico Lleras Acosta, E.S.E., over 
a twenty-year period. Therefore, these data can be 
a starting point for the organization of systematic 
surveillance studies on anti-leprosy drug resistance 
in Colombia, as has been proposed by international 
experts in order to monitor the emergence of 
multidrugresistant bacilli that would hinder the goal 
of eradicating leprosy (30). 
We found that M. leprae circulating between 
1985 and 2004 in Colombia showed resistance to 
dapsone oscillating between 0.06% and 2.4%, and 
Table 5. Distribution of demographic variables according to the susceptibility genotype of the drug under study 
Demographic variables Genotype pa
Wild (%) Mutant (%) Total (%)
Sex
Male
Female
Age at diagnosis of leprosy (years)
<15
21-40
Province of birth
Cundinamarca
Santander
Tolima
Boyaca
Municipality of birth
Bogotá
Puente Nacional
Suaita
Mariquita
Agua de Dios
Barrancabermeja
Province of origin
Cundinamarca
Santander
Municipality of origin
Bogotá
Pereira
Agua de Dios
Landázuri
73.20
26.80
  2.6
54.3
22.00
21.6
17.7
16.4
  2.6
  5.2
  0.9
  3.0
  0.4
  0.4
77.80
  5.1
63.70
  1.70
  0.40
  0.40
69.20
30.80
  5.1
56.4
22.9
40.0
17.1
  5.7
     0
  2.9
  8.60
  8.6
  5.7
  5.7
78.90
13.1
57.90
  5.30
  5.30
  5.30
72.9
27.1
  5.1
49.4
25.6
19.4
15.8
15.8
  3.8
  2.4
  1.6
  1.6
  0.5
  1.3
76.5
  6.1
60.3
  0.9
  1.3
  0.3
   0.590
   0.599
   0.736
   0.811
   0.921
<0.01b
   0.953
   0.060
   0.652
   0.490
 <0.01 b
   0.142
     0.030 b
     0.030 b
   0.760
   0.068
   0.969
   0.191
 <0.01 b
 <0.01 b
a p: Fisher exact test significance, b p<0.05: Significant result of Fisher exact test
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was inexistent in new cases (95% CI). This was also 
the case in the study conducted by Roche in Nepal 
(32) between 1987 and 1999, and in Mexico (29), 
demonstrating that multidrug therapy significantly 
decreases the presence of the dapsone-resistant 
microorganism thanks to the activity of the other 
antibiotics in the regime.
It is important to keep in mind that the number of 
cases studied in this report was much higher than 
in most studies found in the literature, and that 
during the period under study, Colombia had already 
implemented multidrug therapy. Studies in previously 
untreated patients, such as those conducted in 
Indonesia (23), Ethiopia (33), the Philippines (34,35) 
and San Francisco (36), found low frequencies of 
resistance to dapsone, which is similar to our results 
where it was zero. 
Secondary dapsone resistance ranged between 
0.1% and 4.0% (table 1), which suggests that during 
this period, patients at the Centro Dermatológico 
Federico Lleras Acosta, E.S.E., received multidrug 
therapy regularly on account of the new blister 
presentations, and that organisms showing 
resistance to one drug are susceptible to the other 
drugs in multidrug therapy, as its mechanisms of 
action are different.
Regarding rifampicin resistance, it oscillated between 
1.5% and 6.32% for the total population of the 
study, similar data to those reported for the French 
Antilles (25), Indonesia, Myanmar (23) and, recently, 
for Mexico (29). The fact that rifampicin resistance 
among new cases was significantly higher than 
in previously treated cases (p<0.05) ratifies the 
importance of patients’ adherence to multidrug 
therapy and treatment regularity, as non-adherence 
and irregularity are responsible for the emergence of 
resistant strains that will infect new cases. 
Table 6. Distribution of epidemiological variables according to the susceptibility genotype of the drug under study 
Epidemiological variable Genotype p
 Wild (%) Mutant (%) Total (%)
Drugs in previous treatments (n)
Three
Two
One
Regularity in previous MDT
Regular
Not regular
Relationship with index case
1st degree
2nd degree
36.1
  5.3
  5.3
85.0
15.0
16.9
  7.9
45.0
  5.0
38.2
82.4
17.6
12.8
12.8
44.2
  9.4
  6.0
84.9
15.1
16.7
  8.1
 0.224
 0.649
<0.001 b
 0.467
 0.379
 0.300
 0.165
MDT: Multidrug therapy, a p: Fisher exact test significance, b p<0.05: Significant result of Fisher exact test
In general, this result raises concern since it 
may reflect the indiscriminate use of rifampicin 
in the treatment of other pathologies, something 
that could be happening in our setting, thus 
hindering the effectiveness of multidrug therapy 
both in paucibacillary and multibacillary patients. 
Rifampicin, unlike other drugs, is irreplaceable 
because of its high bactericidal power at the 
microorganism’s intracellular level, and because 
in a situation where there is high dapsone-
resistance and low use of clofazimine, it would 
result in reducing the effectiveness of multidrug 
therapy, given that none of the three drugs would 
act optimally. 
We found that resistance to ofloxacin (95% 
confidence interval) oscillated between 0.35% 
and 3.57%, which although lower than the 6.8% 
reported by Maeda (18) in a group of 88 patients 
from Japan, Haiti, Indonesia, Pakistan and the 
Philippines, may be considered a realistic picture of 
our patients’ situation regarding ofloxacin resistance. 
This is even more so when we compared ours to 
the study by Cambau (17), which used only 49 
relapse patients and 34 untreated ones, and where 
resistance reached 13.3%; this can be explained 
by the fact that in Colombia this drug is only added 
to multidrug therapy when patients can buy it with 
their own money. 
In the total study population, we found significant 
differences between resistance in new patients 
versus previously treated ones (p<0.05) (table 4), 
even though the sample size of previously treated 
patients almost doubled that of new patients  and that 
we did not use a random or representative design 
for the number of incidents and prevalent patients in 
Colombia at that time, since we selected samples 
by convenience from the biopsy bank at the Centro 
Dermatológico Federico Lleras Acosta, E.S.E.
a
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Notwithstanding that the number of drug-resistant 
M. leprae samples was low (n=39), it is important 
to underline that 77% of them showed resistance 
to rifampicin alone or combined with another 
drug (figure 1 and table 3). Additionally, 28.3% of 
these presented resistance to ofloxacin alone or 
combined with another drug, which, as explained 
before, reflects the inappropriate use of these drugs 
in our setting. 
In a recent study with samples from three previously-
treated Colombian patients, resistance to rifampicin 
was found in two of them (37), which, even with such a 
small number of patients, concurs with our results.
Results regarding rifampicin among untreated 
cases (4.72% CI95%=1.88-11.2) confirm the 
importance of following international experts’ 
recommendations to start surveillance of rifampicin 
resistance immediately, as it is an irreplaceable 
drug in multidrug therapy.
After analyzing different variables, we found 
that, as documented in other studies (25), drug 
resistance was associated with the place of 
birth within the Santander province (p<0.01) 
(table 5), as well as with not finding bacilli in the 
biopsy (p<0.001), which may be explained by a 
mistaken classification, and finally, with receiving 
monotherapy (p=<0.0001).
Resistance to drugs was not associated with previous 
treatment compliance or with relationship to the 
index case, since it is known that close contact is 
more important than the degree of consanguinity 
(table 6). 
On the other hand, it is important to emphasize that 
drug resistance was not associated with suspicion 
of relapse (p=0.471), as previously observed by Li 
(27), Sekar (28) and da Silva, et al. (38), who showed 
that relapses occur with drug-sensitive strains and 
correspond more to re-infection events. We were 
not able to find evidence of multidrug resistance in 
this study (understood as simultaneous resistance 
to dapsone, rifampicin and ofloxacin), even though 
the samples under study were from multibacillary 
patients with high bacillary populations per gram 
of tissue, which in principle should have facilitated 
finding mutations simultaneously resistant to the 
three drugs, as populations of over 1 x 1020 
microorganisms are needed to obtain one multi-
resistant mutant (39).
We were able to corroborate that from a drug-
resistance point of view, the standard multidrug 
therapy regimes continue to be effective for our 
new and previously treated cases, since the 
proportion of resistant mutants, at its highest range, 
did not exceed 11.2% (table 3). Nevertheless, it is 
necessary to guarantee adherence and regularity in 
multidrug therapy, since the highest drug resistance 
was found for rifampicin, which could hinder the 
effectiveness of this therapy.
We ratify the need to establish immediate drug 
resistance surveillance for rifampicin, dapsone 
and ofloxacin in new and previously treated 
leprosy cases backed by the findings from studies 
on tuberculosis showing that such surveillance is 
cost-effective even in groups with moderate drug 
resistance prevalence. Special attention should 
be paid to transmission reduction achievable 
with the help of intervention measures based on 
surveillance results (40).
According to the results of this study, which 
included cases until 2004, drug-resistant M. 
leprae should be of concern for public health 
authorities in the country since the highest 
proportion of resistance was found for rifampicin. 
There was more resistance to rifampicin among 
new cases than among previously treated patients 
and they were also resistant to ofloxacin, which 
is a second-line drug. All of this jeopardizes the 
effectiveness of multidrug therapy in Colombia 
for both paucibacillary and multibacillary patients 
and reveals the need to increase our knowledge 
on what may have happened regarding this 
problem after 2004. This could be achieved by 
implementing national routine surveillance of drug 
resistance in leprosy.
Conflict of interest
The authors express that there is no conflict of 
interest.
Acknowledgements
The authors want to acknowledge Juan Carlos 
Salazar at the Centro Dermatológico Federico 
Lleras Acosta, E.S.E., Clinical History Group for 
his cooperation in finding the clinical records, and 
to Nelsy Pineda, histotechnologist at the Centro 
Dermatológico Federico Lleras Acosta, E.S.E., for 
her kind cooperation in obtaining the slide cuts from 
the paraffin blocks.
Funding
The study was completely developed and funded by 
the Centro Dermatológico Federico Lleras Acosta, 
E.S.E., code-project 4000-16.2H.
146
Biomédica 2014;34(Supl.1):137-47Guerrero MI, Colorado CL, Torres JF, León CI
References
1. World Health Organization. Chemotherapy of leprosy 
for control programmes. Report of a Study Group. WHO 
Technical Report Series 675, 1982. 
2. Matsuoka M, Kashiwabara Y, Namisato M. A Mycobacterium 
leprae isolate resistant to dapsone, rifampin,ofloxacin and 
sparfloxacin. Int J Lepr Other Mycobact Dis. 2000;68:452-5.
3. Shepard CC, Chang YT. Effect of several anti-leprosy 
drugs on multiplication of human leprosy bacilli in footpads 
of mice. Proc Soc Exp Biol Med. 1962;109:636-8.
4. Musser J. Antimicrobial agent resistance in mycobacteria: 
Molecular genetic inslights. Clin Microbiol Rev. 1995;8:496-514.
5. Williams DL, Gillis TP. Drug-resistant leprosy: Monitoring 
and current status. Review. Lepr Rev. 2012;83:269-81.
6. Kai M, Nguyen Phuc NH, Nguyen HA, Pham TH, Nguyen 
KH, Miyamoto Y, et al. Analysis of drug-resistant strains of 
Mycobacterium leprae in an endemic area of Vietnam. Clin 
Infect Dis. 2011;52:e127-32.
7. Cambau E, Bonnafous P, Perani E, Sougakoff W, 
Ji B, Jarlier V. Molecular detection of rifampicin and 
ofloxacin resistance for patients who experience relapse 
of multibacillary leprosy. Clin Infect Dis. 2001;34:39-45.
8. Matsuoka M, Kashiwabara Y, Liangfen Z, Goto M, Kitajima 
S. A second case of multidrug resistant Mycobacterium leprae 
isolated from a Japanese patient with relapsed lepromatous 
leprosy. Int J Lepr Other Mycobact Dis. 2003;71:240-3.
9. Cambau E, Carthagena L, Chauffour A, Ji B, Jarlier 
V. Dihydropteroate synthase mutations in the folP1 gene 
predict dapsone resistance in relapsed cases of leprosy. 
Clin Infect Dis. 2006;42:238-41.
10. Honore N, Cole ST. Molecular basis of rifampin resistance 
in Mycobacterium leprae. Antimicrob Agents Chemother. 
1993;37:414-8.
11. Honoré N, Perrani E, Telenti A, Grosset J, Cole ST. A 
simple and rapid technique for the detection of rifampin 
resistance in Mycobacterium leprae. Int J Lepr Other 
Mycobact Dis. 1993;61:600-4.
12. Williams DL, Gillis TP. Molecular detection of drug resistance 
in Mycobacterium leprae. Lepr Rev. 2004;75: 118-30.
13. Williams DL, Waguespack C, Eisenach K, Crawford JT, 
Portaels F, Salfinger M, et al. Characterization of rifampin-
resistance in pathogenic mycobacteria. Antimicrob Agents 
Chemother. 1994;38:2380-6.
14. Zhang L, Namisato M, Matsuoka M. A mutation at codon 
516 in the rpoB gene Mycobacterium leprae confers 
resistance to rifampin. Int J Lepr Other Mycobact Dis. 
2004;72:468-72.
15. Kai M, Matsuoka M, Nakata N, Maeda S, Gidoh M, Maeda 
Y, et al. Diaminodiphenilsulfone resistance of Mycobacterium 
leprae due to mutations in the dihydropteroate synthase 
gene. FEMS Microbio Lett. 1999;177:231-5.
16. Williams DL, Spring L, Harris E, Roche P, Gillis TP. 
Dihydropteroate synthase of Mycobacterium leprae and 
dapsone resistance. Antimicrob Agents Chemother. 2000;44: 
1530-7.
17. Cambau E, Perani E, Guillemin I, Jamet P, Ji B. 
Multidrug-resistance to dapsone, rifampicin, and ofloxacin 
in Mycobacterium leprae. Lancet. 1997;349:103-4.
18. Maeda S, Matsuoka M, Nakata N, Kai M, Maeda Y, 
Hashimoto K, et al. Multidrug resistant Mycobacterium 
leprae from patients with leprosy. Antimicrob Agents 
Chemother. 2001;45:3635-9.
19. You EY, KangTJ, Kim SK, Lee SB, Chae GT. Mutations in 
genes related to drug resistance in Mycobacterium leprae 
isolates from leprosy patients in Korea. J Infect. 2005;50:6-11.
20. Ji B. Rifampicin resistant leprosy: A review and a research 
proposal of a pilot study. Lepr Rev. 2002;73:2-8.
21. Shetty VP, Uplekar MW, Antia NH. Primary resistance to 
single and multiple drugs in leprosy--a mouse footpad study. 
Lep Rev. 1996;67:280-6.
22. Ebenezer GJ, Norman G, Joseph GA, Daniel S, Job 
CK. Drug resistant-Mycobacterium leprae results of mouse 
footpad studies from a laboratory in south India. Indian J 
Lepr. 2002;74:301-12.
23. Matsuoka M, Budiawan T, Aye KS, Kyaw K, Tan EV, Cruz 
ED, et al. The frequency of drug resistance mutations in 
Mycobacterium leprae isolates in untreated and relapsed 
leprosy patients from Myanmar, Indonesia and the Philippines. 
Lepr Rev. 2007;78:343-52.
24. Singh P, Busso P, Paniz-Mondolfi A, Aranzazu N, Monot 
M, Honore N, et al. Molecular drug susceptibility testing 
and genotyping of Mycobacterium leprae strains from South 
America. Antimicrob Agents Chemother. 2011;55:2971-3.
25. Grosset JH, Guelpa-Lauras CC, Bobin P, Brucker G, 
Cartel JL, Constant-Desportes M. Study of 39 documented 
relapses of multibacillary leprosy after treatment with rifampin. 
Int J Lepr Other Mycobact Dis. 1989;57:607-14.
26. González AB, Maestre JL, Hernández O, Columbié Y, 
Atrio N, Martín M, et al. Survey for secondary dapsone and 
rifampicin resistance in Cuba. Lepr Rev. 1993;64:128-35.
27. Li HY, Ran SP, Weng TG, Deng XH, Li FT. Relapses in 
leprosy patients treated with rifampicin plus dapsone after 
varying periods of dapsone monotherapy. Indian J Lepr. 
2001;73:1-10.
28. Sekar B, Elangeswaran N, Jayarama E, Rajendran M, 
Kumar S, Vijayaraghavan R, et al. Drug susceptibility of 
Mycobacterium leprae: A retrospective analysis of mouse 
footpad inoculation results from 1983 to 1997. Lepr Rev. 
2002;73:239-44.
29. Matsuoka M, Suzuki Y, Garcia IE, Fafutis-Morris M, 
Vargas-González A, Carreño-Martínez C, et al. Possible 
mode of emergence for drug-resistant leprosy is revealed 
by an analysis of samples from Mexico. Jpn J Infect Dis. 
2010;63:412-6.
30. National JALMA Institute of Leprosy and Other 
Mycobacterial Diseases. Informal consultation on rifampicin 
resistance in leprosy. Lepr Rev. 2007;78:295-305.
31. Torres JF. Estudio de farmacorresistencia y genotipificación 
de M. leprae colombiano período 2000-2004 (tesis). Bogotá: 
Universidad Nacional de Colombia; 2008.
32. Roche PW, Neupane KD, Failbus SS, Butlin CR. Dapsone 
drug resistance in the multidrug therapy era. Int J Lepr Other 
Mycobact Dis. 2000;68:323-5.
33. Warndorff van Diepen T, Aredath SP, Mengistu G. 
Dapsone-resistant leprosy in Addis Ababa: A progress 
report. Lepr Rev. 1984;55:149-57.
147
Biomédica 2014;34(Supl.1):137-47 Drug-resistant Mycobacterium leprae in Colombia
34. Guinto RS, Cellona RV, Fajardo TT, de la Cruz EC. 
Primary dapsone-resistant leprosy in Cebu, Philippines. 
Int J Lepr Other Mycobact Dis. 1981;49:427-30.
35. de la Cruz E, Cellona RV, Balagon MV, Villahermosa 
LG, Fajardo TT Jr, Abalos RM, et al. Primary dapsone 
resistance in Cebu, The Philippines; cause for concern. Int 
J Lepr Other Mycobact Dis. 1996;64:253-6.
36. Gelber RH, Rea TH, Murray LP, Siu P, Tsang M, Byrd SR. 
Primary dapsone-resistant Hansen’s disease in California. 
Experience with over 100 Mycobacterium leprae isolates. 
Arch Dermatol. 1990;126:1584-6.
37. Hernández E, Cardona-Castro N, Rodríguez G, Villegas 
S, Beltrán C, Kimura M, et al. Study of rifampin and 
dapsone resistance in three patients with recurring leprosy. 
Rev Panam Salud Publica. 2008;23:73-7.
38. da Silva Rocha A, Cunha MD, Diniz LM, Salgado C, Aires 
MA, Nery JA, et al. Drug and multidrug resistance among 
Mycobacterium leprae isolates from Brazilian relapsed 
leprosy patients. J Clin Microbiol. 2012;50:1912-7.
39. Williams DL, Gillis TP. Molecular detection of drug 
resistance in Mycobacterium leprae. Review. Lepr Rev. 
2004;75:118-30.
40. Acuña-Villaorduna C, Vassall A, Henostroza G, Seas C, 
Guerra H, Vásquez L, et al. Cost-effectiveness analysis 
of introduction of rapid, alternative methods to identify 
multidrug-resistant tuberculosis in middle-income countries. 
Clin Infect Dis. 2008;47:487-95.
Primers and oligonucleotide sequences used in this study
Oligo name Type Gene
Oligonucleotide
sequences ( 5’ → 3’) bp
folP1d
folP1r
folp53w1
folp53m1
folp53m2
folp53m3
folp53m4
folp53m5
folp55w2
folp55m6
folp55m7
folp55m8
gyrAd
gyrAr
gyrA89w1
gyrA89m1
gyrA91w2
gyrA91m2
gyrA90w3
gyrA90m3
rpoβd
rpoβr
rpoβ407w1
rpoβ407m1
rpoβ410w2
rpoβ410m2
rpoβ410m3
rpoβ420w3
rpoβ420m4
rpoβ420m5
rpoβ425w4
rpoβ425m6
rpoβ425m7
rpoβ425m8
rpoβ427w5
rpoβ427m9
Primer d
Primer r
Wild
Mutant
Mutant
Mutant
Mutant
Mutant
Wild
Mutant
Mutant
Mutant
Primer d
Primer r
Wild
Mutant
Wild
Mutant
Wild
Mutant
Primer d
Primer r
Wild
Mutant
Wild
Mutant
Mutant
Wild
Mutant
Mutant
Wild
Mutant
Mutant
Mutant
Wild
Mutant
folP1
gyrA
rpoβ
5’-agccgacatcagtcgccagtgc-3’
biot-5’-accttgatcctgacgatgct-3’
amino 5’-cgtcggtggcgaatcgacc-3’
amino 5’-cgtcggtggcgaatcggcc-3’
amino 5’-cgtcggtggcgaatcggtc-3’
amino 5’-cgtcggtggcgaatcgatc-3’
amino 5’-cgtcggtggcgaatcgagg-3’
amino 5’-cgtcggtggcgaatcgaga-3’
amino 5’-cggcccggtgccattagga-3’
amino 5’-cggtccggtgccattagga-3’
amino 5’-cggcgcggtgccattagga-3’
amino 5’-cggctcggtgccattagga-3’
5’-agccgacatcagtcgccagtgc-3’
biot-5’-accttgatcctgacgatgct-3’
amino 5’-attaccatccgcacggcgac-3’
amino 5’-attaccatccgcactgcgac-3’
amino 5’-gacgcatcgatttatgacac-3’
amino 5’-gacgtatcgatttatgacac-3’
amino 5’-ggaccgtagccacgctaa-3’
amino 5’-ggaccgtcatcacgctaa-3’
5’-tcctcgtcagcggtcaagta-3’
biot 5’-caggacgtcgaggcgatcac-3’
amino 5’-gccagctgtcgcagttcatg-3’
amino 5’-gccagctgtcggtgttcatg-3’
amino 5’-ttcatggatcagaacaaccc-3’
amino 5’-ttcatgaatcagaacaaccc-3’
amino 5’-ttcatgtatcagaacaaccc-3’
amino 5’-ggcctgacccacaagcgccg-3’
amino 5’-ggcctgacctacaagcgccg-3’
amino 5’-ggcctgaccgacaagcgccg-3’
amino 5’-aagcgccggctgtcggcgct-3’
amino 5’-aagcgccggctgatggcgct-3’
amino 5’-aagcgccggctgttggcgct-3’
amino 5’-aagcgccggctgttcgcgct-3’
amino 5’-gcgctgggcccgggtggttt-3’
amino 5’-gcgccgggcccgggtggttt-3’
388
19
19
19
19
19
19
19
19
19
19
390
20
20
20
20
18
18
304
20
20
20
20
20
20
20
20
20
20
20
20
20
20
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